August 17, 2012

A Randomized, Controlled Study to Assess the Conversion From Calcineurin-Inhibitors to Everolimus After Liver Transplantation-PROTECT


Warning: Invalid argument supplied for foreach() in /nfs/c04/h03/mnt/65750/domains/transplantnow.com/html/wp-content/themes/nephrology/scripts/pubmed.php on line 177

Warning: Invalid argument supplied for foreach() in /nfs/c04/h03/mnt/65750/domains/transplantnow.com/html/wp-content/themes/nephrology/scripts/pubmed.php on line 177

Warning: Invalid argument supplied for foreach() in /nfs/c04/h03/mnt/65750/domains/transplantnow.com/html/wp-content/themes/nephrology/scripts/pubmed.php on line 177
.   .   

Post transplant inmunosuppression with calcineurin inhibitors (CNIs) is associated with renal dysfunction with an estimated rate of advanced CKD of 20% at 5 years. Everolimus is an mTOR inhibitors without the nephrotoxicity of CNIs. In this multicenter, prospective study, the authors evaluate the feasibility and effects of everolimus started at 30 days post liver transplant. They evaluate the safety and complication rate associated with mTOR inhibitors, such as hepatic artery thrombosis and wound healing problems.

Liver Transplantation

Tags: , , , , ,